Kiniksa Pharmaceuticals, Ltd. (KNSA) has 22 open-market insider trades by 10 insiders since 2018. Over the last six months insiders net sold $299K. The most active filer is John F. Paolini.
| Name | Title | Tier | Trades | Value | Last Trade |
|---|---|---|---|---|---|
| Baker Brothers Life Sciences LP | Dir10% Owner | — | 1 | $54.0M | 2024-10-04 |
| Deerfield Mgmt L.P. via James E. Flynn | 10% Owner | — | 1 | $20.5M | 2018-05-29 |
| Thomas Malley | Dir | — | 1 | $11.7M | 2026-05-29 |
| Sanj K. Patel | CEOChairman | — | 3 | $7.1M | 2026-09-01 |
| John F. Paolini | — | — | 5 | $3.5M | 2026-09-01 |
| Barry D. Quart | Dir | — | 3 | $2.9M | 2026-08-19 |
| Mark Ragosa | CFO | — | 2 | $2.5M | 2026-09-01 |
| Thomas W. Beetham | CLOVP | — | 4 | $2.1M | 2021-02-03 |
| Cormorant Asset Management, LP | Dir10% Owner | — | 1 | $1.2M | 2018-05-29 |
| G. Bradley Cole | Dir | — | 1 | $299K | 2026-07-29 |
| Insider | Title | Type | Value | Date |
|---|---|---|---|---|
| Michael R. Megna | CAO | Sell | $369K | 2026-09-03 |
| G. Bradley Cole | Director | Sell | $299K | 2026-07-29 |
| John F. Paolini | — | Sell | $3.1M | 2026-05-01 |
| Sanj K. Patel | CEO & Chairman | Sell | $2.6M | 2026-05-01 |
| Barry D. Quart | Director | Sell | $656K | 2026-04-28 |
| Sanj K. Patel | CEO & Chairman | Sell | $26.4M | 2026-04-28 |
Companies that share insiders with KNSA, and sector peers with recent insider buying. Related by who files, not by how the stocks move.
| Michael R. Megna | CAO | Sell | $309K | 2026-04-09 |
| Ross Moat | COO | Sell | $80K | 2026-04-09 |
| Barry D. Quart | Director | Sell | $345K | 2026-04-06 |
| Sanj K. Patel | CEO & Chairman | Sell | $364K | 2026-04-06 |
| Ross Moat | COO | Sell | $115K | 2026-04-06 |
| Mark Ragosa | CFO | Sell | $1.7M | 2026-03-09 |
| John F. Paolini | — | Sell | $1.8M | 2026-03-02 |
| Barry D. Quart | Director | Sell | $126K | 2026-02-10 |
| Mark Ragosa | CFO | Sell | $772K | 2026-02-09 |